ABSTRACT
Detection of Aspergillus galactomannan (GM) in serum with the Platelia Aspergillus enzyme immunoassay (EIA) is useful for diagnosing invasive aspergillosis. From May 2003 to November 2004, 65 patients who did not develop aspergillosis had at least two positive sera while receiving a beta-lactam treatment (GM index [GMI], >or=0.5). Of the 69 treatment episodes scored, 41 consisted of a beta-lactam other than piperacillin-tazobactam (n=29), namely, amoxicillin-clavulanate (n=25), amoxicillin (n=10), ampicillin (n=3), or phenoxymethylpenicillin (n=2). In all cases, antigenemia became negative 24 h to 120 h upon stopping the antibiotic. Monitoring of 35 patients, including 26 with hematological malignancies, revealed three antigenemia kinetic patterns: each was observed with any drug regimen and consisted of a persistent GMI of >2.0 (65.7%), >0.5, and Subject(s)
Antigens, Fungal/blood
, Aspergillus/isolation & purification
, Fungemia/diagnosis
, Fungemia/drug therapy
, Mannans/blood
, beta-Lactams/therapeutic use
, Aspergillosis/diagnosis
, Aspergillosis/drug therapy
, Aspergillosis/microbiology
, False Positive Reactions
, Fungemia/microbiology
, Galactose/analogs & derivatives
, Humans
, beta-Lactams/administration & dosage